INBS Secures Major London Transport Contract For Fingerprint Drug Testing

Intelligent Bio Solutions Inc. has secured a landmark contract with one of London’s largest public transport operators. The agreement covers 14 operational sites across Greater London and supports over 4,400 employees. The company will deploy its Intelligent Fingerprinting Drug Screening System, a rapid, non-invasive solution designed to enhance workforce safety and compliance. 

“Winning this tender says a lot about the strength of our technology. We offer a system that supports rapid drug testing at scale, meaning fewer people out of action for less time. This minimizes financial loss associated with long wait times and improves overall workforce efficiency. The rapidly rising popularity of our solution is testament to the many benefits it offers businesses of all sizes; from a greater suggestion of impairment and reduced risk to cost savings and a more dignified approach,” said Harry Simeonidis, President and CEO at Intelligent Bio Solutions. 

The transport operator serves more than one million passengers daily with a fleet of over 1,400 low-emission buses, including hybrid, electric, and hydrogen-powered vehicles. The decision to implement INBS’s technology supports the operator’s long-term investments in modernization and safety, making it one of the most forward-looking mass transit providers in the region.

INBS’s solution is already in use across more than 450 accounts in 24 countries and is supported by 18 distribution partners. The company is rapidly expanding across EMEA, Asia Pacific, and the U.S., with FDA clearance for its technology expected in 2025 to facilitate its U.S. market entry.